Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy

Cancer

Volumn 79, Issue 6, 1997, Pages 1216-1224

  Rubenstein, Edward B ^a,k   Gralla, Richard J ^b   Hainsworth, John D ^c   Hesketh, Paul J ^d   Grote, Thomas H ^e   Modiano, Manuel R ^f   Khojasteh, Ali ^g   Kalman, Leonard A ^h   Benedict, Claude R ⁱ   Hahne, William F ^j  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b OCHSNER MEDICAL CENTER   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d ST ELIZABETH'S MEDICAL CENTER   (United States)

^e Forsyth Hematology/Oncology   (United States)

^f Arizona Clinical Research Center   (United States)

^g Columbia Compreh Cancer Care Clinic ^*  (United States)

^h Hematology Oncology Associates   (United States)

ⁱ UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^j SANOFI   (France)

^k UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

5 hydroxytryptamine (5 HT3) receptor antagonist; antiemetic; cyclophosphamide; dolasetron; dose response trial; doxorubicin; emesis; nausea

Indexed keywords

CYCLOPHOSPHAMIDE; DOLASETRON MESILATE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; ANTIEMETIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADMINISTRATION, ORAL; ANTIEMETICS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DOXORUBICIN; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NAUSEA; QUINOLIZINES;

EID: 8044221513     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970315)79:6<1216::AID-CNCR22>3.0.CO;2-1     Document Type: Article

References (47)

1. Cleri Baltzer L. Serotonin antagonists: state of the art management of chemotherapy-induced emesis. Oncol Nurs 1995;2:1-17.
2. Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991;83:613-20.
3. Gralla RJ. Current issues in the management of nausea and vomiting. Ann Oncol 1993;4(3 Suppl):3-7.
4. 3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991;42:551-68.
5. Grunberg SM, Stevenson LL, Russell CA, McDermed JE. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989;7:1137-41.
6. Boxenbaum H, Gillespie T, Heck K, Hahne W. Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 1992;13:693-701.
7. 3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma X glioma cells. Eur J Pharmacol 1992;219:9-13.
8. Shah A, Lanman R, Bhargava V, Weir S, Hahne W. Pharmaco-kinetics of dolasetron following single- and multiple-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 1995;16:177-89.
9. 3 receptors. Drug Dev Res 1993;28:87-93.
10. Harman GS, Omura GA, Ryan K, Hainsworth JD, Cramer MB, Hahne WF. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol 1996;38:323-8.
11. Hesketh PJ, Gandara DR, Hesketh AM, Facada A, Perez EA, Webber LM, et al. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer 1996;4:141-6.
12. Yeilding AL, Bertoli L, Eisenberg PD, Plezia PM, Modiano MR, Khojasteh A, et al. Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. Am J Clin Oncol. 1996;19:619-23.
13. 3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol 1994;17:97-102.
14. Kris MG, Grunberg SM, Gralla RJ, Baltzer L, Zaretsky SA, Lifsey D, et al. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 1994;12:1045-9.
15. Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, et al. Double-blind, randomized comparison of the anti-emetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis. J Clin Oncol 1996;14:2242-9.
16. Chevallier B, Cappelaere P, Splinter T, Fabbro M, Wendling JL, Cals L, et al. A double-blind, multicenter comparison of intravenous dolasetron and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. Support Care Cancer. In press.
17. Beck TM. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. Semin Oncol 1992;19(15 Suppl):20-5.
18. Beck TM, Ciociola AA, Jones SE, Harvey WH, Tchekmedyian NS, Chang A, et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 1993;118:407-13.
19. Bleiberg HH, Spielmann M, Falkson G, Romain D. Anti-emetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose ranging study. Clin Ther 1995;17:38-51.
20. Ettinger D, Eisenberg P, Fitts D. A double-blind comparison of the efficacy of two dose regimens of oral granisetron (1 mg twice, 2 mg once) in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer 1996;78:144-51.
21. Dixon RM, Cramer M, Shah AK, Whitmore J, Benedict CR, Hahne WF. Single-dose, placebo-controlled phase I study of oral dolasetron. Pharmacotherapy 1996;16:245-52.
22. Hunt TL, Cramer M, Christy-Bittel J, Shah AK, Meyerson LJ, Benedict CR. Multiple-dose, placebo-controlled phase I study of oral dolasetron. Pharmacotherapy 1996;16:253-60.
23. Legha SS, Benjamen RS, Mackay B, Ewer M, Wallace S, Valdivieso M, et al. Reduction in doxorubicin cardiotoxicity by prolonged continuous infusion intravenous infusion. Ann Intern Med 1982;96:133-9.
24. Kris MG, Gralla RJ, Clark RA, Tyson LB, Groshen S. Anti-emetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer 1987;60:2816-22.
25. Clark R, Tyson L, Frisone M. A correlation of objective (OBJ) and subjective (SUBJ) parameters in assessing antiemetic regimens (AER) [abstract]. Oncol Nurs Forum 1985; 12(Suppl):232.
26. Grote TJ, Pineda LF, Figlin RA, Pendergrass KB, Hesketh PJ, Karlan BY, et al. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Cancer J Sci Am. In press.
27. Fauser AA, Duclos B, Chemaissani A, Del Favero A, Cognetti F, Diaz-Rubio E, et al. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. Eur J Cancer 1996;32:1523-9.
28. Du Bois A, Meerpohl HG, Vach W, Kommoss FGM, Fenzl E, Pfleiderer A. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study of ondansetron. Eur J Cancer 1992;28:450-7.
29. Aapro MS, Present role of corticosteroids as antiemetics. Recent Results Cancer Res 1991;121:91-100.
30. Aapro MS, Alberts DS. High-dose dexamethasone for prevention of cisplatin-induced vomiting. Cancer Chemother Pharmacol 1981;7:11-4.
31. Allan SG, Farquhar DF, Harrison DJ, Leonard CF. Anti-emetic efficacy of dexamethasone in combination for out-patients receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 1986;18:86-7.
32. Jones AL, Hill AS, Soukop M, Hutcheon AW, Cassidy J, Kaye SB, et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991;338:483-7.
33. Lindley CM, Bernard S, Fields SM. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 1989;7(8):1142-9.
34. Barisano A, Mehl B, Bradbury K. Serotonin antagonists: treatment of chemotherapy-induced emesis. Mt Sinai J Med 1992;59:433-7.
35. 3-receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann Oncol 1993;4:481-4.
36. Addelman M, Erlichman C, Fine S, Warr D, Murray C. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. J Clin Oncol 1990;8:337-41.
37. Watanabe H, Hasegawa A, Shinozaki T, Arita S, Chigira M. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 1995;35:278-82.
38. 3 antagonists ondansetron and granisetron in feline ventricular myocytes. Br J Pharmacol 1994;113:527-35.
39. + conductance in cardiac muscle. Arch Pharmacol 1987;335:692-6.
40. Williams PD, Cohen MI, Turk JA. Electrocardiographic effects of zatosetron and ondansetron, two 5-HT3 receptor antagonists, in anesthetized dogs. Drug Dev Res 1991; 24:277-84.
41. Baltzer L, Kris MG, Hinkley L, Pisters KMW, Lacava PV, Plerri MK, et al. Reversible electrocardiographic interval prolongations following the specific serotonin antagonists ondansetron (OND) and dolasetron mesylate (DM): a possible drug class effect without sequelae [abstract]. Proc Am Soc Clin Oncol 1993;13:1489.
42. Lifsey DS, Gralla RJ, Clark RA, Kline RC. Electrocardiographic changes with serotonin antagonist antiemetics: rate of occurrence and clinical relevance [abstract]. Proc Am Soc Clin Oncol 1993;12:1611.
43. Benedict CR, Arbogast R, Martin L, Patton L, Morrill B, Hahne W. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cadiovasc Pharmacol 1996;28:53-9.
44. Ballard HS, Bottino G, Bottino J. Ondansetron and chest pain [letter]. Lancet 1992;340:1107.
45. c in man. [abstract]. Clin Res 1991;39:718.
46. Williams FM, Rothaul AL, Kane KA, Parratt JR. Antiarrhythmic and electrophysiological effects of ICS 205-930, and antagonist of 5-hydroxytryptamine at peripheral receptors. J Cardiovasc Pharmacol 1985;7:550-5.
47. McDermott S, Songer S, Benedict C, Hahne W. Safety profile of dolasetron. Eur Hosp Pharm 1996;2(1 Suppl):25-31.